Tag Archives: Layton Mills

CannPal Commences Phase 1B Study for Lead Drug Candidate CPAT-01D

Animal health company CannPal Animal Therapeutics Limited (ASX:CP1) (“CannPal” or “the Company”) is pleased to announce that it has commenced Phase 1B of the Pharmacokinetic and Safety study for CPAT-01D, a cannabis-derived veterinary medicine being developed as a pain control in dogs. Key Highlights Commenced Phase 1B of the Pharmacokinetic and Safety study for CPAT-01D, a cannabis-derived … Continue reading

September 5, 2018 Latest News, News

CannPal Receives Ethics Approvals for Phase 1B Study in Dogs

Animal health company CannPal Animal Therapeutics Limited (ASX:CP1) (“CannPal” or “the Company”) is pleased to announce it has received ethics approval to advance its clinical development plans for CPAT-01, a pain control being developed for cats and dogs. Key Highlights CannPal has received ethics approvals to advance the development of its lead drug candidate, CPAT-01, a pain … Continue reading

August 2, 2018 Latest News, News

Geoff Starr Appointed Chairman of CannPal

CannPal Animal Therapeutics (CannPal) has finalized the Company’s board ahead of their upcoming IPO, with the appointment of Mr Geoff Starr as the Company’s Independent Chairman. Mr Starr joins a highly credentialed board, alongside serial entrepreneur Dr Kate Adams, practicing veterinarian and part owner of Bondi Vet, Robert Clifford, food and beverage executive and ex-president … Continue reading

July 10, 2017 Latest News, News